RYH0.F SAREUM HLDGS LS-0125

Healthcare Biotechnology Frankfurt Exchange
0.1430 EUR
Close of Nov 12, 2026
0.1030 0.3760
Market cap
EUR 23.4M
P/E
-
P/B
14.45x
ROE
-194.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Jun 2025.

Is RYH0.F undervalued?

Graham number

The Graham number of SAREUM HLDGS LS-0125 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SAREUM HLDGS LS-0125 fundamental analysis

No fundamental analysis for SAREUM HLDGS LS-0125 yet.

SAREUM HLDGS LS-0125 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SAREUM HLDGS LS-0125

Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. The company's lead product is SDC-1801, a TYK2/JAK1 inhibitor which has completed Phase 1 clinical trial for the treatment of autoimmune diseases. It also develops SDC-1802, a TYK2/JAK1 inhibitor, that is in preclinical stage for cancer and cancer-immunotherapy applications; and SRA737, a clinical-sta…

Full company profile